Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute leukemia in polycythemia vera

S A Landaw

    Seminars in Hematology
    |January 1, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Acute leukemia in polycythemia vera (PV) is complex. Factors like male sex, ethnicity, and 32P treatment influence leukemogenesis, but the disease itself and myelosuppressive agents also play roles.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Deciphering polycythemia.

    Hospital practice (1995)·1996
    Same author

    Recent-onset myelodysplastic syndrome mimicking acute leukemia during infection.

    Annals of hematology·1996
    Same author

    On a dramatic response of refractory anemia with excess blasts in transformation to 5-azacytidine.

    American journal of hematology·1995
    Same author

    Efficacy of alpha interferon and hydroxyurea in late phase refractory myeloproliferative disease.

    Haematologia·1994
    Same author

    Investigations on the role of hemopexin and albumin in plasma clearance and tissue distribution of Sn-protoporphyrin.

    The Journal of laboratory and clinical medicine·1993
    Same author

    Clinical evaluation of serum ferritin as index of iron stores.

    Nutrition (Burbank, Los Angeles County, Calif.)·1993
    Same journal

    Pain in SCD-Many mechanisms and mysteries.

    Seminars in hematology·2026
    Same journal

    The many facets of cardiopulmonary complications in sickle cell disease.

    Seminars in hematology·2026
    Same journal

    Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

    Seminars in hematology·2026
    Same journal

    Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

    Seminars in hematology·2026
    Same journal

    Telomeres biology disorders: the past, the present and the future.

    Seminars in hematology·2026
    Same journal

    Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

    Seminars in hematology·2026
    See all related articles

    Area of Science:

    • Hematology
    • Oncology
    • Medical Science

    Background:

    • Polycythemia vera (PV) is a myeloproliferative neoplasm.
    • The occurrence of acute leukemia (AL) in PV patients is a significant concern.
    • The exact causes and contributing factors to leukemogenesis in PV remain debated.

    Purpose of the Study:

    • To explore the multifaceted factors contributing to the development of acute leukemia in patients with polycythemia vera.
    • To analyze the roles of patient-specific characteristics, disease progression, and treatment modalities in leukemogenesis.
    • To clarify the relationship between polycythemia vera, its treatments, and the subsequent risk of acute leukemia.

    Main Methods:

    • Review of existing literature and case studies on acute leukemia in polycythemia vera.

    Related Experiment Videos

  • Analysis of factors associated with leukemogenesis, including patient demographics, clinical presentation, and treatment history.
  • Comparison of outcomes and incidence of AL across different treatment strategies (e.g., 32P, phlebotomy, chemotherapy).

    • Main Results:

    • Factors such as male gender, ethnic origin, myeloid metaplasia, and early white blood cell precursors are associated with increased AL risk.
    • Treatments like 32P and x-ray therapy show a higher incidence of AL compared to phlebotomy alone, though 32P may offer longer survival.
    • Acute leukemia has been observed in PV patients treated with phlebotomy alone and chemotherapy, suggesting the disease's inherent leukemogenic potential and the impact of myelosuppressive agents.

    Conclusions:

    • The development of acute leukemia in PV is multifactorial, involving inherent disease characteristics, patient-specific factors, and treatment interventions.
    • While certain treatments may increase AL risk, the overall survival benefit and the occurrence of AL in untreated or differently treated patients complicate the attribution solely to specific therapies.
    • Further research is needed to fully elucidate the complex interplay between PV, its management, and the risk of acute leukemia.